Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
暂无分享,去创建一个
Jing Wang | Zehua Wang | Jing Cai | Zehua Wang | Lan Xiao | Lili Yu | Sha Hu | Lili Yu | Zhimin Li | Yi Shen | Jing Cai | Lan Xiao | Lili Yu | Yi Shen | Zhi-min Li | Shanhu Hu | Jing Wang
[1] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[2] V. Rotter,et al. Activated p53 suppresses the histone methyltransferase EZH2 gene , 2004, Oncogene.
[3] Hengbin Wang,et al. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.
[4] James B. Mitchell,et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.
[5] S. Kaye,et al. Ovarian cancer: progress and continuing controversies in management. , 2002, European journal of cancer.
[6] Y. Pommier,et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.
[7] H. Zentgraf,et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells , 2008, International journal of cancer.
[8] A. Wolffe,et al. Epigenetics: regulation through repression. , 1999, Science.
[9] P. Munster,et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. , 2005, Cancer research.
[10] Robert Brown,et al. The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.
[11] P. Finn,et al. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo , 2009, British Journal of Cancer.
[12] J. Köllermann,et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. , 2005, International journal of molecular medicine.
[13] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[14] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] W. Schulz,et al. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer , 2007, Cancer biology & therapy.
[16] F. Hamdy,et al. EZH2 promotes proliferation and invasiveness of prostate cancer cells , 2007, The Prostate.
[17] J. Simon,et al. Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.
[18] K. Nephew,et al. Epigenetic gene silencing in cancer initiation and progression. , 2003, Cancer letters.
[19] O. Halvorsen,et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Wolfgang Fischle,et al. Role of histone modifications in defining chromatin structure and function , 2008, Biological chemistry.
[21] K. Miller,et al. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. , 2009, The Journal of urology.
[22] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[23] R C Young,et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.
[24] Kristian Helin,et al. EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.
[25] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[26] V. Bilim,et al. Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2 , 2008, Clinical Cancer Research.
[27] 木谷 憲典. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas , 2009 .
[28] I. Pogribny,et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. , 2006, Cancer letters.
[29] Johan Eide,et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] T. Utsunomiya,et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.
[31] Annie P. Moseman,et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. , 2006, Cancer research.
[32] A. Ochiai,et al. Enhancer of zeste homolog 2 downregulates E‐cadherin by mediating histone H3 methylation in gastric cancer cells , 2008, Cancer science.
[33] 米満 裕. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma , 2009 .
[34] K. Yanagihara,et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer , 2006, Cancer science.
[35] C. Meijer,et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. , 2004, The American journal of pathology.
[36] Stephen A Boorjian,et al. Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.